Gut

Article	Citations
Gut microbiome and health: mechanistic insights	988
Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19	885
Gut microbiota-derived metabolites as central regulators in metabolic disorders	639
Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN	609
Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report	548
Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome	337
Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome	298
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome	247
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis	235
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) imm	233
Calprotectin: from biomarker to biological function	223
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD	208
Alterations in the human oral and gut microbiomes and lipidomics in COVID-19	184
Helicobacter pyloriresistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community	183
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis	181
Gut microbiota regulate Alzheimer’s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation	179
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting	169
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies	159
Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide	159
Rapid gut dysbiosis induced by stroke exacerbates brain infarction in turn	153
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab	146
Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis	145
F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer	144
Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial	143
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease	141

Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma	139
A faecal microbiota signature with high specificity for pancreatic cancer	139
Diet quality and risk and severity of COVID-19: a prospective cohort study	136
Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade	135
Six-month follow-up of gut microbiota richness in patients with COVID-19	133
Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites	128
Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort	126
Host and gut microbial tryptophan metabolism and type 2 diabetes: an integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies	124
Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis	124
Lactobacillus gallinarummodulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis	120
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?	120
Recent advances in clinical practice: epidemiology of autoimmune liver diseases	120
British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults	119
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes	117
Artificial intelligence and colonoscopy experience: lessons from two randomised trials	117
Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma	117
Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19	115
Disrupted spermatogenesis in a metabolic syndrome model: the role of vitamin A metabolism in the gut–testis axis	114
Dysosmobacter welbionis is a newly isolated human commensal bacterium preventing diet-induced obesity and metabolic disorders in mice	113
Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16	113
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification	113
Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism	111
Current therapies and new developments in NASH	109
Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis	108
Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment	106
Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic func	104
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies	103
Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women	103
Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events	102
Novel therapeutic targets for cholestatic and fatty liver disease	102
Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial	102
Blue poo: impact of gut transit time on the gut microbiome using a novel marker	101
Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett’s oesophagus and provides insights into clinical heterogeneity in reflux d	100
Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis	97
Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity	94
Long-term yield of pancreatic cancer surveillance in high-risk individuals	93
Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment	92
Advancing human gut microbiota research by considering gut transit time	92
Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade	90
Chinese Consensus Report on Family-BasedHelicobacter pyloriInfection Control and Management (2021 Edition)	90
Piecemeal cold snare polypectomy versus conventional endoscopic mucosal resection for large sessile serrated lesions: a retrospective comparison across two successive periods	89
Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulce	89
FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2	87
MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis	86
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future	83
Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update	83
Accuracy of a no-biopsy approach for the diagnosis of coeliac disease across different adult cohorts	82
CXCR2 inhibition enables NASH-HCC immunotherapy	82
Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts	82
Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer	81

Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer	80
Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis	80
Estimating the environmental impact of disposable endoscopic equipment and endoscopes	80
High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+CD8+ T cells	79
Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases	79
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database	78
Bidirectional brain–gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis	78
Underdevelopment of the gut microbiota and bacteria species as non-invasive markers of prediction in children with autism spectrum disorder	76
ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1–TFAM signalling in alcoholic steatohepatitis	75
Updates to the modern diagnosis of GERD: Lyon consensus 2.0	75
Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet	74
Gastric per-oral endoscopic myotomy (G-POEM) for refractory gastroparesis: results from an international prospective trial	72
Interplay between diet and gut microbiome, and circulating concentrations of trimethylamine N-oxide: findings from a longitudinal cohort of US men	71
British Society of Gastroenterology guidelines on the management of functional dyspepsia	71
Dietary macronutrients and the gut microbiome: a precision nutrition approach to improve cardiometabolic health	71
Human and preclinical studies of the host–gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health	71
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial	71
Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis	70
Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea	70
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size	69
Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance	69
Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis	68
Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers	68
Multiomics analysis reveals the presence of a microbiome in the gut of fetal lambs	68
Proton pump inhibitors and risk of gastric cancer: population-based cohort study	68
Mapping the human gut mycobiome in middle-aged and elderly adults: multiomics insights and implications for host metabolic health	68
Impairment of gut microbial biotin metabolism and host biotin status in severe obesity: effect of biotin and prebiotic supplementation on improved metabolism	67
RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer	67
Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases	67
Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients	67
PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF	66
PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicabil	65
Niche-specific functional heterogeneity of intestinal resident macrophages	65
Long-term outcomes after endoscopic treatment for Barrett’s neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period	64
SARS-CoV-2 infection in acute pancreatitis increases disease severity and 30-day mortality: COVID PAN collaborative study	63
Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP)	63
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma	63
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease	61
Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny	61
Organoids in gastrointestinal diseases: from experimental models to clinical translation	60
The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma	60
Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease	60
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis	60
Autoimmune gastritis: long-term natural history in naïveHelicobacter pylori-negative patients	60
Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma	59
Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study	58
Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis	58
Gut commensalParabacteroides distasonisalleviates inflammatory arthritis	58
Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPG	57
Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial	57
Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression	56
Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers	56
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications	55
Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes	55
Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts	55
Large-scale, national, family-based epidemiological study onHelicobacter pyloriinfection in China: the time to change practice for related disease prevention	55
Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease	55
Oncogenetic landscape of lymphomagenesis in coeliac disease	54
6α-hydroxylated bile acids mediate TGR5 signalling to improve glucose metabolism upon dietary fiber supplementation in mice	54
COVID-19 and liver disease	53
Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial	53
A mechanism by which gut microbiota elevates permeability and inflammation in obese/diabetic mice and human gut	52
Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc–xCT	51
Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis	51
Genomic evolution and diverse models of systemic metastases in colorectal cancer	51
Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model	49
Genetic architectures of proximal and distal colorectal cancer are partly distinct	49
Microbial transmission, colonisation and succession: from pregnancy to infancy	49
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis	49
Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection	49
Gestational diabetes is driven by microbiota-induced inflammation months before diagnosis	48
PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma	48
From the origin of NASH to the future of metabolic fatty liver disease	48
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells	47
NAIL: an evolutionarily conserved lncRNA essential for licensing coordinated activation of p38 and NFκB in colitis	46
Roseburia intestinalisgenerated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+T cells	46
Understanding neuroimmune interactions in disorders of gut–brain interaction: from functional to immune-mediated disorders	46
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis	46
Faecal metabolome and its determinants in inflammatory bowel disease	46
Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study	45

Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study	45
Comparison of lumen-apposing metal stents versus double-pigtail plastic stents for infected necrotising pancreatitis	45
A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer	44
Prostaglandin E2 receptor PTGER4-expressing macrophages promote intestinal epithelial barrier regeneration upon inflammation	44
Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma	44
Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo	44
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications	44
Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry	44
Stool microRNA profiles reflect different dietary and gut microbiome patterns in healthy individuals	43
Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease	43
Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment	43
Rapid resolution of COVID-19 after faecal microbiota transplantation	43
Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals	43
Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination	43
Non-compliance with colonoscopy after a positive faecal immunochemical test doubles the risk of dying from colorectal cancer	43
Immunopathogenesis and environmental triggers in coeliac disease	42
Rescue of male fertility following faecal microbiota transplantation from alginate oligosaccharide-dosed mice	42
Senolytic elimination of Cox2-expressing senescent cells inhibits the growth of premalignant pancreatic lesions	42
Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science	42
Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures	41
Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B	41
Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC	41
Over-the-scope-clips versus standard treatment in high-risk patients with acute non-variceal upper gastrointestinal bleeding: a randomised controlled trial (STING-2)	41
Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System	41
Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort	40
Dietary fibres and IBS: translating functional characteristics to clinical value in the era of personalised medicine	40
Helicobacter pyloripromotes colorectal carcinogenesis by deregulating intestinal immunity and inducing a mucus-degrading microbiota signature	40
What to do about the leaky gut	40
Randomised comparison of postpolypectomy surveillance intervals following a two-round baseline colonoscopy: the Japan Polyp Study Workgroup	40
Human gastric microbiota transplantation recapitulates premalignant lesions in germ-free mice	40
Acetyltransferase fromAkkermansia muciniphilablunts colorectal tumourigenesis by reprogramming tumour microenvironment	40
Serotonin is elevated in COVID-19-associated diarrhoea	40
Efficacy ofHelicobacter pylorieradication therapy for functional dyspepsia: updated systematic review and meta-analysis	40
Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study)	40
Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity	40
Application of Lyon Consensus criteria for GORD diagnosis: evaluation of conventional and new impedance-pH parameters	39
Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale	39
Activated intestinal muscle cells promote preadipocyte migration: a novel mechanism for creeping fat formation in Crohn’s disease	39
Irritable bowel syndrome: treatment based on pathophysiology and biomarkers	39
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease	37
International consensus to standardise histopathological scoring for small bowel strictures in Crohn’s disease	37
A novel peptide protects against diet-induced obesity by suppressing appetite and modulating the gut microbiota	37
Computational modelling suggests that Barrett’s oesophagus may be the precursor of all oesophageal adenocarcinomas	37
Neutrophils prevent rectal bleeding in ulcerative colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis	37
GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity	37
Gut microbiota influence anastomotic healing in colorectal cancer surgery through modulation of mucosal proinflammatory cytokines	36
Gut as viral reservoir: lessons from gut viromes, HIV and COVID-19	36
CCT3-LINC00326axis regulates hepatocarcinogenic lipid metabolism	36
The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment)	35
Gluten-induced RNA methylation changes regulate intestinal inflammation via allele-specific XPO1 translation in epithelial cells	35
Biopsy and blood-based molecular biomarker of inflammation in IBD	35
Synbindin restrains proinflammatory macrophage activation against microbiota and mucosal inflammation during colitis	35
Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis	34
Activated regulatory T-cells promote duodenal bacterial translocation into necrotic areas in severe acute pancreatitis	34
Maternal obesity, pregnancy weight gain, and birth weight and risk of colorectal cancer	34
Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas	34
Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target	34
British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophi	34
Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency	34
Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma	34
Proton pump inhibitors and risk of colorectal cancer	34
Multicentre randomised controlled trial on virtual chromoendoscopy in the detection of neoplasia during colitis surveillance high-definition colonoscopy (the VIRTUOSO trial)	34
Chief cell plasticity is the origin of metaplasia following acute injury in the stomach mucosa	33
Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma	33
Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis	33
Pain patterns in chronic pancreatitis: a nationwide longitudinal cohort study	33
EUS-guided drainage of large walled-off pancreatic necroses using plastic versus lumen-apposing metal stents: a single-centre randomised controlled trial	32
Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma	32
Targeting tumour-intrinsic N7-methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy	32
Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial	32
Akkermansia muciniphilacounteracts the deleterious effects of dietary emulsifiers on microbiota and host metabolism	32
MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression	32
Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus	32
Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial	32
Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy	31
Iqgap3-Ras axis drives stem cell proliferation in the stomach corpus during homoeostasis and repair	31
Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment	31
Association between Brachyspira and irritable bowel syndrome with diarrhoea	31
Obesity-associated deficits in inhibitory control are phenocopied to mice through gut microbiota changes in one-carbon and aromatic amino acids metabolic pathways	31
Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer	31
Radiology-guided percutaneous approach is superior to EUS for performing liver biopsies	31
Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B	30
Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis	30
ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4	30
Third Asia-Pacific consensus recommendations on colorectal cancer screening and postpolypectomy surveillance	30
Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response	30
A novel unconventional T cell population enriched in Crohn’s disease	30
IL-17A-producing CD8+T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts	29
Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers	29
Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn’s disease highlight earliest events of pathogenesis	29
Identification and validation of a multivariable prediction model based on blood plasma and serum metabolomics for the distinction of chronic pancreatitis subjects from non-pancreas disease control su	29
Unfavourable intrauterine environment contributes to abnormal gut microbiome and metabolome in twins	29
Agonist that activates the µ-opioid receptor in acidified microenvironments inhibits colitis pain without side effects	29
Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment	29
Post-acute COVID-19 syndrome and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance	29